Dossier assessment
Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Dolutegravir in HIV-1 infection: added benefit in adult patients
Additional information
Federal Joint Committee (G-BA)
2014-08-07 A G-BA decision was published.
Project details
- Project no.
- A14-08
- Commission
- Commission awarded on 10.02.2014 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed